Eli Lilly & Co. closed 18.86% short of its 52-week high of $972.53, which the company reached on August 22nd.

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

The Chief Executive of Eli Lilly has told the BBC that he is doubtful tariffs could bring manufacturing jobs to the US whilst ...

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

Sangamo Therapeutics has stacked up $18 million cash from Eli Lilly in a licensing deal that will let the pharma use the ...

Shares of Sangamo Therapeutics Inc (NASDAQ: SGMO) surged 30.2% following the announcement of a significant licensing agreement with pharmaceutical giant Eli Lilly and Company (NYSE: LLY ). The deal ...

Genomic medicine company Sangamo Therapeutics said it entered a license agreement with Eli Lilly, under which Lilly received rights to employ Sangamo's proprietary capsid, STAC-BBB, for up to five ...

Sangamo Therapeutics (SGMO) announced it has entered into a license agreement with Eli Lilly (LLY), allowing Lilly to leverage Sangamo’s novel ...

UNICEF works to increase support and understanding of non-communicable diseases (NCDs) in childhood in low- and middle-income countries.

With blockbuster GLP-1 drugs such as Ozempic, Wegovy from Danish drug maker Novo Nordisk, and Mounjaro from American pharma ...

A retrospective review reports that pregnant women with pityriasis rosea onset before 15 weeks have higher rates of ...

Trump announced a 10% tariff on all U.S. trading partners, in addition to higher reciprocal tariffs on the EU and China. But ...